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In order to evaluate the use of an algorithm based on a procalcitonin (PCT) cut-off value as
a means of guiding antibiotic therapy, 319 hospitalised children with uncomplicated
community-acquired pneumonia (CAP) were randomised 1:1 to be treated on the basis of
the algorithm or in accordance with standard guidelines. The children in the PCT group did
not receive antibiotics if their PCT level upon admission was <0.25 ng/mL, and those receiving
antibiotics from the time of admission were treated until their PCT level was 0.25 ng/mL.
The final analysis was based on 155 patients in the PCT group and 155 in the control group.
In comparison with the controls, the PCT group received significantly fewer antibiotic prescrip-
tions (85.8% vs 100%; p < 0.05), were exposed to antibiotics for a shorter time (5.37 vs 10.96
days; p < 0.05), and experienced fewer antibiotic-related adverse events (3.9% vs 25.2%;
p < 0.05), regardless of CAP severity. There was no significant between-group difference in
recurrence of respiratory symptoms and new antibiotic prescription in the month following
enrollment. The results of this first prospective study using a PCT cut-off value to guide anti-
biotic therapy for pediatric CAP showed that this approach can significantly reduce antibiotic
use and antibiotic-related adverse events in children with uncomplicated disease. However,
because the study included mainly children with mild to moderate CAP and the risk of the
use of the algorithm-based approach was not validated in a relevant number of severe cases,
further studies are needed before it can be used in routine clinical practice.
ª 2011 Elsevier Ltd. All rights reserved.55032203; fax: þ39 02 50320206.
imi.it (N. Principi).
1 Elsevier Ltd. All rights reserved.
1940 S. Esposito et al.Introduction
Pediatric community-acquired pneumonia (CAP) is
common, particularly in the first years of life.1 In many
cases, it is due to viruses, uncomplicated by bacterial
superinfection, has a mild course and, consequently, should
not receive antibiotic therapy.2,3 However, because of the
difficulties in identifying its specific etiology clinically and
radiologically,4e6 most children with CAP are treated with
antibiotics without the causative agent being known. This
leads to a considerable over-use of antibiotics7,8 that
increases the risk of bacterial resistance, the incidence of
drug-related adverse events, and therapeutic costs.
A number of attempts have been made to differentiate
viral and bacterial infections, and rationalise antibiotic use
by means of easily determined biomarkers.9e14 Those based
on serum procalcitonin (PCT) levels have recently aroused
considerable interest because preliminary data demon-
strate that, also in children, PCT concentrations markedly
increase in the presence of bacteremic infection (including
CAP), and are more useful than C-reactive protein (CRP)
and interleukin-6 levels or white blood cell (WBC) counts in
distinguishing bacterial from viral CAP.11e16 On the basis of
these data, it was thought that determining PCT levels may
predict bacteremic CAP as a mean of severity, make it
easier to identify the patients for whom antibiotic
prescription is really mandatory and guide the duration of
antibiotic administration.17 Some studies found a severity-
dependent increase in serum PCT, with the highest levels
(significantly different from those found in viral cases)
being observed in cases of severe invasive bacterial
CAP.17,18 It has been shown that the use of PCT-guided
therapy markedly reduces antibiotic prescriptions in
adults with lower respiratory tract infections without
affecting clinical outcomes19e26; however, differently from
experience performed in adults, no precise cut-off PCT
concentration capable of guiding antibiotic administration
in children with CAP has ever been established. Further-
more, as sometimes only a very small number of patients
had PCT levels considered useful for differentiating viral
and bacterial CAP, it has even been concluded that PCT
levels are not very useful when making therapeutic
choices.15,16
The aim of this study was to evaluate the use of an
algorithm based on a PCT cut-off value as a means of
guiding the management of antibiotic therapy in hospital-
ised children with uncomplicated CAP.
Materials and methods
Study design
This prospective, single-centre randomised study consecu-
tively enrolled children with CAP who were hospitalised in
the Department of Maternal and Pediatric Sciences of the
University of Milan, Milan, Italy. The enrolled children were
randomised to receive antibiotics on the basis of a PCT
algorithm (PCT group) or in accordance with evidence-
based guidelines (control group), according to previous
experience performed in adults with CAP.19e26 The protocol
was approved by the Ethical Committee of the FondazioneIRCCS Ca’ Granda Ospedale Maggiore Policlinico, and
written informed consent was obtained from both parents
or the legal guardian of each child.
Study patients
Fig. 1 shows the trial flow chart. Between October 2008 and
September 2010, 419 children with CAP were hospitalised in
the Department and assessed for eligibility. The criteria for
participating in the study included all of the following: an
age of >1 month and <14 years; a diagnosis of CAP made on
the basis of clinical signs and symptoms (i.e. a history of
fever or cough, tachypnea, dyspnea or respiratory distress,
and breathing with grunting or wheezing sounds with rales)
and confirmed by chest radiography (i.e. the presence of
pulmonary infiltration or segmental or lobar consolidation);
no demonstrable complications (i.e. pleural effusion,
empyema, lung necrosis, pneumatocele). Children were
also excluded if they had received antibiotics in the 10 days
preceding admission or if they were suffering from an
underlying chronic disease (i.e. anatomic abnormalities of
the respiratory tract, immunological deficits, progressing
neurological conditions, psychomotor retardation, congen-
ital heart disease, hemoglobinopathy), severe malnutrition
or other concurrent infections. The radiological readings
were always made by the same pediatric radiologist who
was blinded to the clinical information. Moreover, no
microbiological evaluation was performed in agreement
with what usually happens in routinary pediatric practice
(i.e., antimicrobial therapy for pediatric CAP is chosen on
the basis of epidemiologic data and guidelines considering
the limitations in obtaining an adequate sample for
appropriate and comprehensive microbiological
evaluation).
The demographic, clinical history and physical exami-
nation data were recorded in a previously prepared elec-
tronic chart together with the results of the laboratory
tests and chest radiography. Fever was defined as an axil-
lary temperature of >37.5 C, and tachypnea on the basis
of the World Health Organisation criteria.27 CAP severity
was assessed using the pediatric criteria of the British
Thoracic Society.28
Study protocol
The patients were randomised to the PCT or control group
using a previously prepared computer-generated random-
isation list and sealed envelope. Antibiotics were not
administered to the children with admission PCT levels of
<0.25 ng/mL, but were immediately given in the case of
higher values. The untreated children were given antibi-
otics only if their PCT levels increased to 0.25 ng/mL, and
continued the therapy until the levels had returned to this
value. The children who received antibiotics from the time
of admission were treated until their PCT levels were
>0.25 ng/mL, and resumed antibiotics only if their PCT
levels subsequently increased to more than this value.
The Italian Society of Pediatrics (SIP) guidelines for the
management of pediatric CAP were used when choosing the
antibiotic regimen.29 In the case of mild CAP, these guide-
lines recommend the use of oral amoxicillin for children
419 children with CAP assessed for eligibility 
319 enrolled and randomly assigned to treatment 
48 received antibiotics for >24 hrs 
before admission 
31 had complicated CAP (21 
empyema, 6 pneumatocele, 4 
necrotising pneumonia) 
15 refused consent 
6 were aged <1 month 
160 to the procalcitonin 
group
159 to the control group 
155 included in the 
analysis (all come back 
at follow-up visits)
155 included in the 
analysis (all come back 
at follow-up visits) 
5 withdrew 
consent 
4 withdrew 
consent 
Figure 1 Study flow chart.
Procalcitonin for pediatric pneumonia therapy 1941aged <4 years and oral clarithromycin for those aged 4
years; in severe cases regardless of age, the recommended
treatment is oral amoxicillin-clavulanate or intravenous
(i.v.) cefotaxime plus oral or i.v. clarithomycin.
The children in the control group were always treated in
accordance with the SIP guidelines: antibiotic monotherapy
chosen on the basis of age if mild; combined beta-lactam
and macrolide therapy if severe. The duration of adminis-
tration in the control group was that recommended by the
SIP (i.e. 7e14 days depending on disease severity).
All of the patients were clinically reassessed every day
during hospitalisation. Untreated children showing no
reduction in the clinical signs and symptoms of disease
after three days could be treated with antibiotics regard-
less of their PCT levels. Moreover, in the case of severe
clinical deterioration and regardless of their PCT levels, the
children in both groups could be treated with antibiotics (if
previously untreated) or their treatment could be modified
on the basis of their pediatrician’s judgment.
The children were discharged when they had been fever-
free for 48 h, their vital signs had been stable for 24 h, and
they had returned to their pre-admission status. Upon
discharge, the parents were given a leaflet providing
general trial information for their primary care pediatri-
cians, and all were instructed to return to the hospital for
check-ups 14  2 and 28  3 days after admission or in the
case of any new episode of fever with respiratory symp-
toms. At these follow-up visits, they were evaluated by
a blinded researcher (CT) who defined the outcome. Chil-
dren were considered definitively cured when no respira-
tory sign and symptom were found at the control visit.
Recurrence was defined as the reappearance of respiratory
signs and symptoms at the control visit. Adverse events
potentially derived from antibiotic use (i.e., abdominalpain, vomiting, diarrhea, skin eruptions) were daily moni-
tored in all the children receiving these drugs during the
period of their administration and in the five days after. For
each of them, the total duration in days of persistence and
the need for specific drug administration was registered.
All of the clinical and laboratory data collected during
the hospital stay and follow-up were recorded in the same
electronic chart in which the admission data were
recorded.
Serum PCT measurements
PCT was measured using a rapid and sensitive immunoassay
with a functional sensitivity of 0.06 ng/mL (KryptornPCT,
Brahms, Henningsdorf, Germany). The coefficients of vari-
ation at concentrations of 0.1 ng/mL, 0.25 ng/mL, 0.5 ng/
mL and 10 ng/mL were respectively 16%, 7%, 5% and 3%.
The blood samples for measuring serum PCT were taken
as early as possible, typically upon admission or at most
within 6 h of admission, and the results were available
60 min later. PCT levels were measured every two days
until discharge, and during the two follow-up visits. The
analyses were made by the validated laboratory of the
Department of Maternal and Pediatric Sciences of the
University of Milan.
Statistical analysis
Pre-study power calculations (with 90% power) showed that
76 patients in each group were necessary to detect a 15%
lower antibiotic use, considering that 100% of children
hospitalized for CAP were treated with antibiotics and
assuming a two-tailed test and a 5% level of significance.
1942 S. Esposito et al.Since we planned to analyse the data in subgroups of mild
and severe CAP, we doubled the number of patients per
group (nZ 152). Thus, we decided to enrol 160 patients in
each group to allow for a 5% drop-out subject. The discrete
variables were expressed as absolute numbers (percent-
ages), and the continuous variables as mean
values  standard deviation (SD), unless stated otherwise.
The comparability of the treatment groups group was
analysed using the Fisher’s exact test, the chi-square test,
a two-sample t-test or the non-parametric ManneWhitney
U-test, as appropriate. A double-sided p value of <0.05 was
considered significant. The statistical analyses were made
using SAS software for Windows v. 9.1 (SAS Institute, Cary,
NC, USA). The authors kept and analysed all of the data.Results
Of the children assessed for eligibility, 48 had received
antibiotics in the 10 days preceding admission, 31 had
complicated CAP (21 pleural effusion or empyema, six
pneumatocele, and four necrotising CAP), six were aged <1
month, and the parents of 15 refused to sign the informed
consent form. Consequently, 319 children were enrolled
and randomly assigned 1:1 to the treatment groups but, as
consent was withdrawn during the study in nine cases (five
in the PCT group and four in the control group), the final
analysis was based on 310 children (155 per group). All the
310 children came to the follow-up visits 14  2 and 28  3
days after admission. Table 1 shows the demographic
characteristics of the analysed children. The two groups
were comparable in terms of gender, mean age, race, the
mean number of respiratory infections (including CAP) in
their history, the number of antibiotic courses in the
previous six months, urban residence, the number of
siblings, the duration of breast-feeding, exposure toTable 1 Demographic characteristics of the study children upo
No. of males (%)
Mean age  SD, yrs
<4 yrs, No. (%)
4 yrs, No. (%)
Caucasians, No. (%)
Mean number of respiratory infections in previous 12 months  S
Patients with a history of CAP, No. (%)
Mean number of antibiotic courses in previous 6 months  SD
Urban residence, No. (%)
At least one older sibling, No. (%)
Breast-feeding 3 months, No. (%)
Exposure to cigarette smoke, No. (%)
Full-time child-care attendance,a No. (%)
History of allergy, No. (%)
Hospitalisations in previous 3 months, No. (%)
Vaccinated with heptavalent pneumococcal conjugated vaccine,
Vaccinated with influenza vaccine, No. (%)
CAP: community-acquired pneumonia; SD: standard deviation.
a 5e6 days/week, 6e8 h/day. No significant between-group differecigarette smoke, child-care attendance, history of allergy,
previous hospitalisations, and previous vaccinations against
pneumococcal infections and influenza. Table 2 shows the
clinical, laboratory and radiographic findings upon admis-
sion. More than half of the children in both groups had
a temperature of >38.5 C, and a peripheral oxygen satu-
ration (SpO2) in room air of 92% or slightly higher. Conse-
quently, the CAP was classified as severe in 79 patients in
PCT group (50.9%) and 76 in the control group (49.0%). The
mean CRP, WBC, neutrophil percentage and PCT values
were similar in the two groups. PCT levels were <0.25 ng/
mL in 24 of the children in the PCT group (15.5%) and 29 of
those of the control group (18.7%). The radiographic find-
ings were also similar in the two groups.
Fig. 2 shows the data regarding antibiotic administration
by randomisation group and CAP severity. Twenty-four
children in the PCT group (15.5%: 21 [87.5%] with mild
CAP and three [12.5%] with severe CAP) were never treated
with antibiotics because their PCT concentrations were
<0.25 ng/mL until discharge. They did not experience any
respiratory problems during follow-up and were considered
completely cured at the control visits. Among the 131
children in the PCT group who received antibiotic therapy,
PCT monitoring led to its discontinuation after two days in
two cases (1.5%), after four days in six (4.6%), after six days
in 49 (37.4%) and after eight days in 61 (46.6%); only 10
children (11.5%) received antibiotics for more than eight
days, one of whom (with severe CAP) continued for 14 days.
In three cases (2.3%), the discontinuation of antibiotic
treatment after four days was followed by an increase in
PCT values to 0.25 ng/mL (respectively 0.50, 0.75 and
0.90). These children, who had persistent respiratory
symptoms, therefore resumed antibiotic therapy, which
was stopped on day 10 in all cases when their PCT levels
had returned to <0.25 ng/mL and they had clinically
improved. On the contrary, all of the 155 controls receivedn admission.
Procalcitonin
group (n Z 155)
Controls (n Z 155)
85 (54.8) 88 (56.8)
4.31  3.76 4.67  3.96
76 (49.0) 74 (47.7)
79 (51.0) 81 (52.3)
139 (89.7) 143 (92.3)
D 2.97  1.85 2.63  1.79
9 (5.8) 6 (3.9)
1.88  0.67 1.52  0.64
152 (98.1) 155 (100.0)
61 (39.4) 57 (36.8)
91 (58.7) 96 (61.9)
39 (25.2) 33 (21.3)
133 (85.8) 128 (82.6)
22 (14.2) 18 (11.6)
1 (0.6) 1 (0.6)
No. (%) 52 (33.5) 58 (37.4)
9 (5.8) 11 (7.1)
nce.
Table 2 Clinical, laboratory and radiographic findings
upon admission.
Procalcitonin
group (n Z 155)
Controls
(n Z 155)
Clinical findings, mean value  SD
Axillary temperature,
peak day value (C)
38.8  0.85 38.6  0.96
SpO2 in room air, % 91  4 92  5
Laboratory findings, mean value  SD
CRP, mg/dL 8.8  4.7 7.1  3.9
WBC, cells/mL 16,300  4250 15,155  6140
Neutrophils, % 76  14 67  19
PCT, ng/mL 1.82  1.76 1.79  1.88
Positive blood cultures,
No. (%)
2 (1.3) 1 (0.6)
Radiographic findings,
No. (%)
Reticulonodular
infiltrate
55 (35.5) 60 (38.7)
Segmental or lobar
consolidation
61 (39.3) 58 (37.4)
Bilateral consolidation 39 (25.2) 37 (23.9)
CRP: C-reactive protein; PCT: procalcitonin; SD: standard
deviation; SpO2: peripheral oxygen saturation; WBC: white
blood cell count. No significant between-group difference.
Procalcitonin for pediatric pneumonia therapy 1943antibiotics for at least seven days, 128 (82.6%) for 10 days,
39 (25.2%) for 12 days, and 21 (13.5%) for 14 days. The
between-group differences in both the rate and duration of
antibiotic exposure was statistically significant (p < 0.05).
Table 3 shows the data regarding outcomes by random-
isation group and CAP severity. The evolution of CAP was
similar in the two groups, as shown by the duration of fever,
oxygen therapy and hospitalisation; the number of respi-
ratory problems during the follow-up and the incidence of
recurrences were also quite similar. One child in the PCT
group (0.6%) and six (3.9%) in the control group were
brought to the Department 2e3 weeks after discharge
because of persistent cough, and all were diagnosed as
having acute bronchitis; their PCT levels were alwaysFigure 2 Antibiotic (Ab) exposure by treatment group and
CAP severity.<0.25 ng/mL. The child in the PCT group and four of the
controls were treated with antibiotics. All were considered
cured at the time of the final visit 28 days after admission.
Possibly or probably antibiotic-related adverse events
were significantly more frequent among the control group
than in the PCT group (25.2% vs 3.9%; p < 0.05) regardless
of CAP severity. The most frequent adverse event in both
groups was diarrhea registered in about 70% of the children
who experienced signs and symptoms potentially due to
antibiotic administration in both groups. None of the study
children discontinued antibiotic administration because of
an adverse event and none received any therapy to face
these problems.Discussion
In most of the pediatric CAPs, particularly in those with
mild to moderate signs and symptoms, etiology of the
disease is not routinely performed because methods to
identify the infecting agent(s) are generally unreliable in
children or, when able to give correct information, too
invasive to be ethically acceptable. Consequently, because
CAP can have a rapid negative evolution, almost all the
children receive an antibiotic treatment even when the
disease could be due to viruses. However, because an
excessive use of antibiotics can lead to negative conse-
quences, methods to rationalize antibiotic treatment of
pediatric CAP are considered mandatory. This is the first
prospective study using an algorithm based on a PCT cut-off
value to guide antibiotic therapy in children with CAP of
unknown etiology, and the results show that this approach
can significantly reduce antibiotic use and antibiotic-
related adverse events.
The cut-off value of 0.25 ng/mL was the same as that
used in some adult clinical trials to select subjects with
lower respiratory tract infections in whom antibiotic
administration was to be strongly discouraged or recom-
mended.23e25 As in these trials, our findings demonstrated
that the algorithm based on a PCT level of 0.25 ng/mL was
not inferior to the clinical guidelines for pediatric CAP
therapy in terms of clinical outcomes, and was more
effective in reducing antibiotic exposure and antibiotic-
related adverse events. A number of studies have shown
that only PCT values of between 0.5 and 2 ng/mL are useful
in differentiating viral and bacterial CAP10e12,15; lower
values are not sufficiently sensitive and specific because of
the significant overlap of data collected from children with
viral, bacterial or mixed infection.
However, our data seem to overcome the problem of the
differentiation of viral from bacterial infections because
that they clearly suggest that a PCT cut-off value of
0.25 ng/mL can be useful in separating the cases of pedi-
atric CAP that, regardless of etiology, do not need antibi-
otic treatment or, even if due to bacteria, can be treated
for a shorter time than that usually recommended by the
guidelines. The use of the algorithm allowed 15% of the
children to avoid antibiotics altogether, and significantly
reduced the duration of administration in most of the cases
treated upon admission, without any increased risk of
a negative evolution even in severe cases. None of the
untreated children experienced any recurrence of CAP or
Table 3 Outcomes by treatment group and CAP severity.
Variables Procalcitonin group (n Z 155) Control group (n Z 155)
Mild CAP
(n Z 76)
Severe CAP
(n Z 79)
Mild CAP
(n Z 79)
Severe CAP
(n Z 76)
Duration of fever, mean days  SD 2.01  1.76 2.88  2.01 2.16  1.96 2.52  2.22
Duration of oxygen therapy, mean days  SD 0 3.4  1.99 0 3.88  1.58
Length of hospital stay, mean days  SD 4.7  2.88 5.01  2.43 5.61  1.99 5.93  1.70
Outcomes on day 28  3
Recurrence of respiratory symptoms, No. (%) 0 (0.0) 1 (1.3) 2 (2.5) 4 (5.3)
New antibiotic prescription, No. (%) 0 (0.0) 1 (1.3) 1 (1.3) 3 (3.9)
Antibiotic-related adverse effects, No. (%) 1 (1.3)^ 5 (6.3) 18 (22.7) 21 (27.6)
CAP: community-acquired pneumonia; n.a.: not applicable; SD: standard deviation. *p < 0.05 vs severe CAP in procalcitonin group;
^p < 0.05 vs mild CAP in control group; p < 0.05 vs severe CAP in control group. No other significant between-group difference.
1944 S. Esposito et al.respiratory symptoms in the following weeks, and the three
who resumed antibiotics after discontinuation because of
slight increases in their PCT levels did not show any clinical
deterioration. Furthermore, regardless of disease severity,
the outcomes in the children in the PCT group who were
treated with antibiotics were substantially positive and no
different from those of the children who received antibi-
otics for longer in accordance with the Italian guidelines.
Fewer antibiotic prescriptions to treat respiratory
infections have a number of advantages for patients and
society as a whole. As found in this study, the incidence of
antibiotic-related adverse events is significantly reduced,
but so is the cost of treatment and the potential risk of the
emergence of bacterial resistance. All of these positive
consequences have been recorded in adult studies19e26 but,
given the frequency of respiratory tract infections in the
first years of life30 and the present recommendations for
the treatment of CAP in children,1,6,28,29,31,32 it is possible
that they may be even more significant in pediatrics. With
very few exceptions, most experts suggest systematically
administering antibiotics in all cases of CAP because of the
difficulty in identifying its etiology in young and uncoop-
erative patients.1,6,28,29,31,32 Moreover, although not
precisely defined, the recommended duration of adminis-
tration is never less than seven 7 days even in mild
cases.1,6,28,29,31,32
Further studies are needed before this PCT-based algo-
rithm can be used in everyday practice. Our trial involved
a relatively small number of children, all of whom had
uncomplicated CAP. Consequently, it is underpowered to
evaluate the safety of this algorithm approach when used in
children with more severe disease or in patients suffering
from bacterial CAP due to pathogens with lower sensitivity
to commonly used antibiotics. It was also conducted in
a hospital, where the monitoring of disease outcomes is
continuous and significantly closer than is possible in
a community setting. We did not assess whether the PCT-
guided approach to pediatric CAP can be used by the
primary care pediatricians who diagnose and treat the
majority of cases, and where the near-patient test for PCT
determination at the moment available can be easily per-
formed. Some adult studies have clearly shown that general
practitioners are usually reluctant to use repeat blood
sampling,21 and unwilling to avoid antibiotic therapy orreduce the duration of administration in patients with
CAP.22 However, on the basis of our results, it is reasonable
to believe that the introduction of a PCT-based algorithm
may be extremely useful in managing pediatric CAP in the
community as well as in hospitals.Conflict of interest
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